GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 10,857 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 10,857 shares of the business’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $143.89, for a total value of $1,562,213.73. Following the sale, the chief executive officer owned 14,237 shares in the company, valued at approximately $2,048,561.93. This represents a 43.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.

Katherine Stueland also recently made the following trade(s):

• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total transaction of $579,619.92.
• On Wednesday, October 29th, Katherine Stueland sold 2,158 shares of GeneDx stock. The shares were sold at an average price of $136.54, for a total transaction of $294,653.32.

GeneDx Stock Up 0.3%

NASDAQ WGS opened at $136.32 on Friday. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87. The company has a current ratio of 2.71, a quick ratio of 2.59 and a debt-to-equity ratio of 0.18. The stock’s 50 day moving average is $140.74 and its two-hundred day moving average is $115.51. The company has a market capitalization of $3.94 billion, a price-to-earnings ratio of 1,514.67 and a beta of 1.99.

GeneDx (NASDAQ:WGS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.28 by $0.21. GeneDx had a return on equity of 20.22% and a net margin of 0.52%.The business had revenue of $116.74 million for the quarter, compared to analyst estimates of $104.33 million. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeneDx

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Raymond James Financial Inc. boosted its position in shares of GeneDx by 25.8% during the first quarter. Raymond James Financial Inc. now owns 333,376 shares of the company’s stock worth $29,525,000 after purchasing an additional 68,331 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of GeneDx by 150.9% in the second quarter. Harbor Capital Advisors Inc. now owns 39,979 shares of the company’s stock worth $3,690,000 after acquiring an additional 24,042 shares in the last quarter. MRA Advisory Group acquired a new stake in shares of GeneDx during the second quarter worth about $298,000. Rhumbline Advisers lifted its holdings in shares of GeneDx by 42.7% during the 2nd quarter. Rhumbline Advisers now owns 27,610 shares of the company’s stock valued at $2,549,000 after purchasing an additional 8,258 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. acquired a new position in shares of GeneDx in the 1st quarter valued at approximately $488,000. Institutional investors own 61.72% of the company’s stock.

Analyst Ratings Changes

WGS has been the topic of a number of recent analyst reports. Wells Fargo & Company set a $155.00 price target on shares of GeneDx and gave the company an “equal weight” rating in a research report on Monday. Wall Street Zen cut GeneDx from a “buy” rating to a “hold” rating in a report on Saturday, November 1st. Guggenheim restated a “buy” rating and set a $170.00 target price (up previously from $115.00) on shares of GeneDx in a report on Wednesday, October 29th. BTIG Research lifted their price target on GeneDx from $165.00 to $200.00 and gave the company a “buy” rating in a report on Friday, December 12th. Finally, Canaccord Genuity Group set a $160.00 price objective on shares of GeneDx and gave the stock a “buy” rating in a report on Wednesday, October 29th. Seven investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $134.78.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.